UTHR: United Therapeutics Inc. Market Capitalization

United Therapeutics Corp - graphic logo of issuer UTHR

United Therapeutics (UTHR) possesses significant pricing power due to patent protection of unique drug delivery methods, which complements its primary revenue from the sale of innovative treatments for PAH and xenotransplantation. The asset's market valuation dynamics on the GURU.Markets platform stand at 25.10, while the business relies on the solvency of insurance systems that fund therapy for patients with critical cardiovascular pathologies.

UTHR United Therapeutics Corporation: Market Value in the range 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for United Therapeutics (UTHR)

- stock price and consensus target price:
Stock Quotes United Therapeutics Corporation|UTHR - Analyst Forecast Prices
- market capitalization information:
Market Capitalization United Therapeutics Corp|UTHR - Value Adjusted for Debt and Cash
- issuer book value statistics:
Net Assets per Single Share United Therapeutics|UTHR - Accounting Value of Company|Market Value to Book Value Ratio unither.com|UTHR - Company Total Asset Base
- debt and solvency information:
Debt to Equity United Therapeutics|UTHR - Long-Term Liabilities to Equity|Short-Term Debt to Capital United Therapeutics Inc.|UTHR - Company Cumulative Debt|Debts to Book Capitalization United Therapeutics Corp|UTHR - Company Long-Term Liabilities|Company Short-Term Debts United Therapeutics|Quick Ratio unither.com
- business earnings and investment ratios data:
UTHR - Net Profit|Expected Profit United Therapeutics|UTHR - Price to Earnings Ratio|Forward P/E Multiple unither.com|UTHR - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio United Therapeutics|UTHR - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) United Therapeutics|UTHR - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth unither.com|UTHR - Earnings per share growth this year|Expected earnings per share growth for next year United Therapeutics
- company sales and revenue statistics:
UTHR - Company Sales Revenue|Company Projected Revenue United Therapeutics Corporation|UTHR - Price-to-Sales Ratio|Forward P/S Multiple United Therapeutics Corp|UTHR - Revenue Dynamics YoY (Last Twelve Months)
Initial company analysis:United Therapeutics Inc. UTHR
Original product of United Therapeutics Inc.

United Therapeutics investments in energy-efficient infrastructure and net-zero carbon centers directly impact the long-term attractiveness of the business for ESG funds. The company's current market capitalization reflects the aggregate value of all shares, accumulating investor expectations regarding future profits, while the consolidation of this metric on the chart signals a temporary equilibrium between market optimism and macroeconomic pressure.

Competitors of United Therapeutics (UTHR)

Market Value Vertex Pharmaceuticals Inc. VRTX|Alnylam Corp - Market Value|INSM - Market Value|Market Value BMRN (biomarin.com)|BridgeBio Corp (BBIO) - Market Value|BGM - Market Capitalization|Market Value Cogent Corp|Xeris Pharma (XERS) - Market Capitalization|Market Value Keros Pharma (KROS)|ARCT: Market Valuation|Market Capitalization ETON (Eton Corp)|Kamada (KMDA) - Market Value|Fulcrum Corp - Market Capitalization|abeonatherapeutics.com (ABEO) - Market Valuation|MREO: Market Capitalization|protalix.com (PLX) - Market Capitalization|PLRX (Pliant Rx) - Market Capitalization|Market Capitalization appliedtherapeutics.com|Market Value Rein Therapeutics, Inc. (RNTX)|Market Value GELS (Gelteq)|Market Capitalization AYTU (aytubio.com)|Market Capitalization chemomab.com (CMMB)|SRXH: Market Valuation|Market Valuation PLRZ|AEZS: Market Capitalization|Market Value CTD Holdings (CYTH)|INZY (Inozyme Pharma) - Market Capitalization|Market Capitalization RPHM (Reneo Pharmaceuticals, Inc.)|Market Valuation CSCI (COSCIENS Biopharma)